Journal
NATURE COMMUNICATIONS
Volume 7, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms11074
Keywords
-
Categories
Funding
- British Heart Foundation (BHF) [PG/13/12/30017, PG/11/23/28801]
- BHF Intermediate Fellowship [FS/09/046/28043]
- Medical Research Council Research Grant [G0802004]
- British Heart Foundation [PG/09/052/27833, PG/12/76/29852, PG/13/12/30017, FS/09/046/28043, PG/14/70/31039, PG/14/71/31063, PG/11/23/28801] Funding Source: researchfish
- Medical Research Council [MR/M008908/1, G0802004] Funding Source: researchfish
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [NC/S01302/1] Funding Source: researchfish
- MRC [G0802004, MR/M008908/1] Funding Source: UKRI
Ask authors/readers for more resources
The heart responds to pathological overload through myocyte hypertrophy. Here we show that this response is regulated by cardiac fibroblasts via a paracrine mechanism involving plasma membrane calcium ATPase 4 (PMCA4). Pmca4 deletion in mice, both systemically and specifically in fibroblasts, reduces the hypertrophic response to pressure overload; however, knocking out Pmca4 specifically in cardiomyocytes does not produce this effect. Mechanistically, cardiac fibroblasts lacking PMCA4 produce higher levels of secreted frizzled related protein 2 (sFRP2), which inhibits the hypertrophic response in neighbouring cardiomyocytes. Furthermore, we show that treatment with the PMCA4 inhibitor aurintricarboxylic acid (ATA) inhibits and reverses cardiac hypertrophy induced by pressure overload in mice. Our results reveal that PMCA4 regulates the development of cardiac hypertrophy and provide proof of principle for a therapeutic approach to treat this condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available